Roshini Yapa
Nephrology · Monterey, CANPI 1205254695
Payments from drug & device makers
Across 24 payments — averaging $52.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$862
- Otsuka America Pharmaceutical, Inc.$126
- AstraZeneca$78
- GSK$65
- OPKO Pharmaceuticals, LLC$45
- Travere Therapeutics, Inc.$29
- plus $48 from 2 others
What the payments were for
- Consulting fees$86269%
- Food & beverage$34728%
- Education$454%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 1 | $862 |
| Otsuka America Pharmaceutical, Inc. | 6 | $126 |
| AstraZeneca | 4 | $78 |
| GSK | 3 | $65 |
| OPKO Pharmaceuticals, LLC | 3 | $45 |
| Travere Therapeutics, Inc. | 5 | $29 |
| Vifor Pharma, Inc. | 1 | $26 |
| Fresenius USA Marketing, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,254 in reported general payments places this provider in the 45th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 16 | $52,084 |
| Sevelamer Carbonate | 59 | $24,967 |
| Lanthanum Carbonate | 12 | $24,156 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $14,122 |
| JardianceEmpagliflozin | 14 | $13,365 |
| EliquisApixaban | 12 | $11,320 |
| Cinacalcet Hcl | 16 | $8,752 |
| FarxigaDapagliflozin Propanediol | 17 | $7,793 |
| Bumetanide | 75 | $4,738 |
| Calcium Acetate | 16 | $3,207 |
| Potassium Citrate ErPotassium Citrate | 13 | $2,873 |
| Allopurinol | 162 | $1,618 |
| Carvedilol | 151 | $1,420 |
| Amlodipine Besylate | 153 | $1,278 |
| Potassium Chloride | 32 | $1,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $78 | $7,79317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,341 nephrology providers in California.
Other nephrology in Monterey
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.